ישראל -
עברית -
Ministry of Health
בוסולפקס
tzamal bio-pharma ltd - busulfan - תמיסה להזרקה - busulfan 60 mg / 10 ml - busulfan - busulfan - for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation.
ישראל -
עברית -
Ministry of Health
בוסוליף 100 מג
pfizer pharmaceuticals israel ltd - bosutinib as monohydrate - טבליות מצופות פילם - bosutinib as monohydrate 100 mg - bosutinib
ישראל -
עברית -
Ministry of Health
בוסוליף 500 מג
pfizer pharmaceuticals israel ltd - bosutinib as monohydrate - טבליות מצופות פילם - bosutinib as monohydrate 500 mg - bosutinib
ישראל -
עברית -
Ministry of Health
בוסולפקס
tzamal bio-pharma ltd - busulfan - תמיסה להזרקה - busulfan 60 mg / 10 ml - busulfan
ישראל -
עברית -
Ministry of Health
בוסוליף 400 מג
pfizer pharmaceuticals israel ltd - bosutinib as monohydrate - טבליות מצופות פילם - bosutinib as monohydrate 400 mg - bosutinib
ישראל -
עברית -
Ministry of Health
טריטייס קומפ 2.5 מג 12.5 מג
sanofi israel ltd - hydrochlorothiazide; ramipril - טבליה - ramipril 2.5 mg; hydrochlorothiazide 12.5 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.
ישראל -
עברית -
Ministry of Health
טריטייס קומפ 5 מג 25 מג
sanofi israel ltd - hydrochlorothiazide; ramipril - טבליה - ramipril 5 mg; hydrochlorothiazide 25 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.
ישראל -
עברית -
Ministry of Health
תרדיפרון
padagis israel agencies ltd, israel - ferrous sulfate - טבליה - ferrous sulfate 247.25 mg - iron bivalent, oral preparations - prevention and treatment of iron deficiency anemia.
ישראל -
עברית -
Ministry of Health
מולטאק
sanofi israel ltd - dronedarone - טבליות מצופות פילם - dronedarone 400 mg - dronedarone - dronedarone - multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (af). due to its safety profile, multaq should only be prescribed after alternative treatment options have been considered.multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure.